Guido Sauter

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6713942/publications.pdf

Version: 2024-02-01

253	13,109	71102	26613
papers	citations	41 h-index	107 g-index

257	257	257	15170
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nature Medicine, 1998, 4, 844-847.	30.7	3,661
2	AIB1, a Steroid Receptor Coactivator Amplified in Breast and Ovarian Cancer. Science, 1997, 277, 965-968.	12.6	1,514
3	Prognostic utility of the recently recommended histologic classification and revised TNM staging system of renal cell carcinoma. Cancer, 2000, 89, 604-614.	4.1	424
4	Tissue microarray (TMA) technology: miniaturized pathology archives for high-throughputin situ studies. Journal of Pathology, 2001, 195, 72-79.	4.5	355
5	Genomic Deletion of PTEN Is Associated with Tumor Progression and Early PSA Recurrence in ERG Fusion-Positive and Fusion-Negative Prostate Cancer. American Journal of Pathology, 2012, 181, 401-412.	3.8	278
6	Changes in Cytoskeletal Protein Composition Indicative of an Epithelial-Mesenchymal Transition in Human Micrometastatic and Primary Breast Carcinoma Cells. Clinical Cancer Research, 2005, 11, 8006-8014.	7.0	277
7	Microarrays of bladder cancer tissue are highly representative of proliferation index and histological grade. Journal of Pathology, 2001, 194, 349-357.	4.5	274
8	Tissue microarrays (TMAs) for high-throughput molecular pathology research. International Journal of Cancer, 2001, 94, 1-5.	5.1	220
9	Intratumor DNA Methylation Heterogeneity Reflects Clonal Evolution in Aggressive Prostate Cancer. Cell Reports, 2014, 8, 798-806.	6.4	219
10	Clinical Utility of Quantitative Gleason Grading in Prostate Biopsies and Prostatectomy Specimens. European Urology, 2016, 69, 592-598.	1.9	212
11	Molecular Evolution of Early-Onset Prostate Cancer Identifies Molecular Risk Markers and Clinical Trajectories. Cancer Cell, 2018, 34, 996-1011.e8.	16.8	190
12	Tissue microarrays in drug discovery. Nature Reviews Drug Discovery, 2003, 2, 962-972.	46.4	178
13	Ki67 LABELLING INDEX: AN INDEPENDENT PREDICTOR OF PROGRESSION IN PROSTATE CANCER TREATED BY RADICAL PROSTATECTOMY. Journal of Pathology, 1996, 178, 437-441.	4.5	174
14	Deep Learning for Natural Language Processing in Urology: State-of-the-Art Automated Extraction of Detailed Pathologic Prostate Cancer Data From Narratively Written Electronic Health Records. JCO Clinical Cancer Informatics, 2018, 2, 1-9.	2.1	150
15	BAZ2A (TIP5) is involved in epigenetic alterations in prostate cancer and its overexpression predicts disease recurrence. Nature Genetics, 2015, 47, 22-30.	21.4	141
16	The polyphosphateâ€“factor XII pathway drives coagulation in prostate cancer-associated thrombosis. Blood, 2015, 126, 1379-1389.	1.4	117
17	High Ki67 expression is an independent good prognostic marker in colorectal cancer. Journal of Clinical Pathology, 2016, 69, 209-214.	2.0	114
18	Heterogeneity of amplification of HER2, EGFR, CCND1 and MYC in gastric cancer. BMC Gastroenterology, 2015, 15, 7.	2.0	101

#	Article	IF	Citations
19	Tissue microarrays for comparing molecular features with proliferation activity in breast cancer. International Journal of Cancer, 2006, 118, 2190-2194.	5.1	100
20	Mitochondrial mutations drive prostate cancer aggression. Nature Communications, 2017, 8, 656.	12.8	100
21	Androgen Receptor Deregulation Drives Bromodomain-Mediated Chromatin Alterations in Prostate Cancer. Cell Reports, 2017, 19, 2045-2059.	6.4	99
22	Clinical significance of different types ofp53gene alteration in surgically treated prostate cancer. International Journal of Cancer, 2014, 135, 1369-1380.	5.1	95
23	Random forest-based modelling to detect biomarkers for prostate cancer progression. Clinical Epigenetics, 2019, 11, 148.	4.1	89
24	Discovery of new DNA amplification loci in prostate cancer by comparative genomic hybridization. Prostate, 2001, 46, 184-190.	2.3	76
25	Heterogeneity and chronology of PTEN deletion and ERG fusion in prostate cancer. Modern Pathology, 2014, 27, 1612-1620.	5.5	69
26	Up-regulation of Biglycan is Associated with Poor Prognosis and PTEN Deletion in Patients with Prostate Cancer. Neoplasia, 2017, 19, 707-715.	5.3	65
27	Chromosome-9 loss detected by fluorescencein situ hybridization in bladder cancer. International Journal of Cancer, 1995, 64, 99-103.	5.1	61
28	CGH, cDNA and Tissue Microarray Analyses ImplicateFGFR2Amplification in a Small Subset of Breast Tumors. Analytical Cellular Pathology, 2001, 22, 229-234.	2.1	60
29	Improved procedure for fluorescence in situ hybridization on tissue microarrays. Cytometry, 2001, 45, 83-86.	1.8	60
30	Marked genetic similarities between hepatitis B virus-positive and hepatitis C virus-positive hepatocellular carcinomas. Journal of Pathology, 2000, 192, 307-312.	4.5	58
31	Marked Prognostic Impact of Minimal Lymphatic Tumor Spread in Prostate Cancer. European Urology, 2018, 74, 376-386.	1.9	58
32	PTEN loss detection in prostate cancer: comparison of PTEN immunohistochemistry and PTEN FISH in a large retrospective prostatectomy cohort. Oncotarget, 2017, 8, 65566-65576.	1.8	56
33	FOCAL NEUROENDOCRINE DIFFERENTIATION LACKS PROGNOSTIC SIGNIFICANCE IN PROSTATE CORE NEEDLE BIOPSIES. Journal of Urology, 1998, 160, 406-410.	0.4	55
34	TMPRSS2-ERG Fusions Are Strongly Linked to Young Patient Age in Low-grade Prostate Cancer. European Urology, 2014, 66, 978-981.	1.9	54
35	EGF-r gene copy number changes in renal cell carcinoma detected by fluorescencein situ hybridization. , 1998, 184, 424-429.		52
36	Prevalence of Î²III-tubulin (TUBB3) expression in human normal tissues and cancers. Tumor Biology, 2017, 39, 101042831771216.	1.8	51

#	Article	IF	Citations
37	Chromosomal imbalances in small cell carcinomas of the urinary bladder. , 1999, 189, 230-235.		50
38	IMP3 overexpression occurs in various important cancer types and is linked to aggressive tumor features: A tissue microarray study on 8,877 human cancers and normal tissues. Oncology Reports, 2018, 39, 3-12.	2.6	50
39	Î²III-Tubulin Overexpression Is an Independent Predictor of Prostate Cancer Progression Tightly Linked to ERG Fusion Status and PTEN Deletion. American Journal of Pathology, 2014, 184, 609-617.	3.8	48
40	Patterns of TPD52 overexpression in multiple human solid tumor types analyzed by quantitative PCR. International Journal of Oncology, 2014, 44, 609-615.	3.3	48
41	Does the extent of variant histology affect oncological outcomes in patients with urothelial carcinoma of the bladder treated with radical cystectomy?. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 21.e1-21.e9.	1.6	48
42	CDKN2A Mutation Analysis, Protein Expression, and Deletion Mapping of Chromosome 9p in Conventional Clear-Cell Renal Carcinomas. American Journal of Pathology, 2001, 158, 593-601.	3.8	46
43	Cyclin D1 overexpression lacks prognostic significance in superficial urinary bladder cancer. Journal of Pathology, 1999, 188, 44-50.	4.5	45
44	Extreme intratumour heterogeneity and driver evolution in mismatch repair deficient gastro-oesophageal cancer. Nature Communications, 2020, 11, 139.	12.8	44
45	Overexpression of thymidylate synthase (TYMS) is associated with aggressive tumor features and early PSA recurrence in prostate cancer. Oncotarget, 2015, 6, 8377-8387.	1.8	44
46	Cytoplasmic Accumulation of Sequestosome 1 (p62) Is a Predictor of Biochemical Recurrence, Rapid Tumor Cell Proliferation, and Genomic Instability in Prostate Cancer. Clinical Cancer Research, 2015, 21, 3471-3479.	7.0	43
47	Mesothelin Expression in Human Tumors: A Tissue Microarray Study on 12,679 Tumors. Biomedicines, 2021, 9, 397.	3.2	42
48	Comparative genomic hybridization reveals frequent chromosome 13q and 4q losses in renal carcinomas with sarcomatoid transformation. , 1998, 185, 382-388.		41
49	Integrating Tertiary Gleason 5 Patterns into Quantitative Gleason Grading in Prostate Biopsies and Prostatectomy Specimens. European Urology, 2018, 73, 674-683.	1.9	40
50	Concurrent deletion of 16q23 and PTEN is an independent prognostic feature in prostate cancer. International Journal of Cancer, 2015, 137, 2354-2363.	5.1	39
51	HER2 Status in Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma for Entry to the TRIO-013/LOGiC Trial of Lapatinib. Molecular Cancer Therapeutics, 2017, 16, 228-238.	4.1	38
52	Prevalence of Syndecan-1 (CD138) Expression in Different Kinds of Human Tumors and Normal Tissues. Disease Markers, 2019, 2019, 1-11.	1.3	38
53	Heterogeneity in Dx³Amico classificationâ€“based low-risk prostate cancer: Differences in upgrading and upstaging according to active surveillance eligibility. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 329.e13-329.e19.	1.6	37
54	Tissue Microarrays. Methods in Molecular Biology, 2016, 1381, 53-65.	0.9	37

#	Article	IF	Citations
55	Heterogeneity of chromosome 17 and erbB-2 gene copy number in primary and metastatic bladder cancer. Cytometry, 1995, 21, 40-46.	1.8	36
56	Reprogramming of the ERRÎ± and ERÎ± Target Gene Landscape Triggers Tamoxifen Resistance in Breast Cancer. Cancer Research, 2015, 75, 720-731.	0.9	36
57	Response to olaparib in a PALB2 germline mutated prostate cancer and genetic events associated with resistance. Journal of Physical Education and Sports Management, 2019, 5, a003657.	1.2	36
58	13q deletion is linked to an adverse phenotype and poor prognosis in prostate cancer. Genes Chromosomes and Cancer, 2018, 57, 504-512.	2.8	35
59	Pussycats and baby tigers: non-invasive (pTa) and minimally invasive (pT1) bladder carcinomas are not the same!. , 1998, 185, 339-341.		34
60	High RNA-binding motif protein 3 expression is an independent prognostic marker in operated prostate cancer and tightly linked to ERG activation and PTEN deletions. European Journal of Cancer, 2014, 50, 852-861.	2.8	34
61	A Tertiary Gleason Pattern in the Prostatectomy Specimen and its Association with Adverse Outcome after Radical Prostatectomy. Journal of Urology, 2014, 192, 97-102.	0.4	34
62	HOXB13 overexpression is an independent predictor of early PSA recurrence in prostate cancer treated by radical prostatectomy. Oncotarget, 2015, 6, 12822-12834.	1.8	34
63	Cyclin D1 gene amplification is highly homogeneous in breast cancer. Breast Cancer, 2016, 23, 111-119.	2.9	33
64	p63 expression in human tumors and normal tissues: a tissue microarray study on 10,200 tumors. Biomarker Research, 2021, 9, 7.	6.8	33
65	Up-regulation of lysophosphatidylcholine acyltransferase 1 (LPCAT1) is linked to poor prognosis in breast cancer. Aging, 2019, 11, 7796-7804.	3.1	33
66	Diagnostic and prognostic impact of cytokeratin 18 expression in human tumors: a tissue microarray study on 11,952 tumors. Molecular Medicine, 2021, 27, 16.	4.4	32
67	Epidermal growth factor receptor (EGFR) in salivary gland carcinomas: Potentials as therapeutic target. Oral Oncology, 2012, 48, 991-996.	1.5	31
68	IL22BP Mediates the Antitumor Effects of Lymphotoxin Against Colorectal Tumors in Mice and Humans. Gastroenterology, 2020, 159, 1417-1430.e3.	1.3	31
69	p16 overexpression and 9p21 deletion are linked to unfavorable tumor phenotype in breast cancer. Oncotarget, 2016, 7, 81322-81331.	1.8	31
70	Partial PTEN deletion is linked to poor prognosis in breast cancer. BMC Cancer, 2015, 15, 963.	2.6	30
71	The prognostic value of SUMO1/Sentrin specific peptidase 1 (SENP1) in prostate cancer is limited to ERG-fusion positive tumors lacking PTEN deletion. BMC Cancer, 2015, 15, 538.	2.6	30
72	Reduced <scp>AZGP1</scp> expression is an independent predictor of early <scp>PSA</scp> recurrence and associated with ERGâ€fusion positive and <scp>PTEN</scp> deleted prostate cancers. International Journal of Cancer, 2016, 138, 1199-1206.	5.1	30

#	Article	IF	Citations
73	High-Level Î³-Glutamyl-Hydrolase (GGH) Expression is Linked to Poor Prognosis in ERG Negative Prostate Cancer. International Journal of Molecular Sciences, 2017, 18, 286.	4.1	30
74	E-Cadherin expression in human tumors: a tissue microarray study on 10,851 tumors. Biomarker Research, 2021, 9, 44.	6.8	30
75	Genomic deletion of chromosome 12p is an independent prognostic marker in prostate cancer. Oncotarget, 2015, 6, 27966-27979.	1.8	30
76	Expression of the immune checkpoint receptor TIGIT in Hodgkinâ€™s lymphoma. BMC Cancer, 2018, 18, 1209.	2.6	28
77	Up regulation of Rho-associated coiled-coil containing kinase1 (ROCK1) is associated with genetic instability and poor prognosis in prostate cancer. Aging, 2019, 11, 7859-7879.	3.1	28
78	Carcinomas of the renal pelvis associated with smoking and phenacetin abuse:p53 mutations and polymorphism of carcinogen-metabolising enzymes. , 1998, 79, 531-536.		27
79	Cytoplasmic accumulation of ELAVL1 is an independent predictor of biochemical recurrence associated with genomic instability in prostate cancer. Prostate, 2016, 76, 259-272.	2.3	27
80	Loss of SOX9 Expression Is Associated with PSA Recurrence in ERG-Positive and PTEN Deleted Prostate Cancers. PLoS ONE, 2015, 10, e0128525.	2.5	26
81	HDAC1 overexpression independently predicts biochemical recurrence and is associated with rapid tumor cell proliferation and genomic instability in prostate cancer. Experimental and Molecular Pathology, 2015, 98, 419-426.	2.1	26
82	Internal standardization of LA-ICP-MS immuno imaging via printing of universal metal spiked inks onto tissue sections. Journal of Analytical Atomic Spectrometry, 2016, 31, 801-808.	3.0	26
83	Immunohistochemically detected IDH1R132H mutation is rare and mostly heterogeneous in prostate cancer. World Journal of Urology, 2018, 36, 877-882.	2.2	26
84	Deletion lengthening at chromosomes 6q and 16q targets multiple tumor suppressor genes and is associated with an increasingly poor prognosis in prostate cancer. Oncotarget, 2017, 8, 108923-108935.	1.8	26
85	Cdc7 overexpression is an independent prognostic marker and a potential therapeutic target in colorectal cancer. Diagnostic Pathology, 2015, 10, 125.	2.0	25
86	Heterogeneity of ERG expression in prostate cancer: a large section mapping study of entire prostatectomy specimens from 125 patients. BMC Cancer, 2016, 16, 641.	2.6	24
87	Aberrant expression of the microtubule-associated protein tau is an independent prognostic feature in prostate cancer. BMC Cancer, 2019, 19, 193.	2.6	24
88	High homogeneity of MMR deficiency in ovarian cancer. Gynecologic Oncology, 2020, 156, 669-675.	1.4	24
89	Î² III-tubulin overexpression is linked to aggressive tumor features and genetic instability in urinary bladder cancer. Human Pathology, 2017, 61, 210-220.	2.0	23
90	Prevalence of CD8+ cytotoxic lymphocytes in human neoplasms. Cellular Oncology (Dordrecht), 2020, 43, 421-430.	4.4	23

#	Article	IF	Citations
91	Loss of ALCAM expression is linked to adverse phenotype and poor prognosis in breast cancer: A TMA-based immunohistochemical study on 2,197 breast cancer patients. Oncology Reports, 2014, 32, 2628-2634.	2.6	22
92	Prognostic and diagnostic role of PSA immunohistochemistry: A tissue microarray study on 21,000 normal and cancerous tissues. Oncotarget, 2019, 10, 5439-5453.	1.8	22
93	The Combination of DNA Ploidy Status and PTEN/6q15 Deletions Provides Strong and Independent Prognostic Information in Prostate Cancer. Clinical Cancer Research, 2016, 22, 2802-2811.	7.0	21
94	Loss of Somatostatin Receptor Subtype 2 in Prostate Cancer Is Linked to an Aggressive Cancer Phenotype, High Tumor Cell Proliferation and Predicts Early Metastatic and Biochemical Relapse. PLoS ONE, 2014, 9, e100469.	2.5	20
95	p16 upregulation is linked to poor prognosis in ERG negative prostate cancer. Tumor Biology, 2016, 37, 12655-12663.	1.8	20
96	MMR Deficiency is Homogeneous in Pancreatic Carcinoma and Associated with High Density of Cd8-Positive Lymphocytes. Annals of Surgical Oncology, 2020, 27, 3997-4006.	1.5	20
97	DNA Aneuploidy, S-phase fraction, nuclear p53 positivity, and survival in non-small-cell lung carcinoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 1997, 431, 173-179.	2.8	19
98	Loss of H2Bub1 Expression is Linked to Poor Prognosis in Nodal Negative Colorectal Cancers. Pathology and Oncology Research, 2016, 22, 95-102.	1.9	19
99	Tumor volume improves the long-term prediction of biochemical recurrence-free survival after radical prostatectomy for localized prostate cancer with positive surgical margins. World Journal of Urology, 2017, 35, 199-206.	2.2	19
100	Apurinic/apyrimidinic endonuclease 1 (APE1/Refâ€1) overexpression is an independent prognostic marker in prostate cancer without TMPRSS2:ERG fusion. Molecular Carcinogenesis, 2017, 56, 2135-2145.	2.7	19
101	PSCA expression is associated with favorable tumor features and reduced PSA recurrence in operated prostate cancer. BMC Cancer, 2018, 18, 612.	2.6	19
102	p53 overexpression is a prognosticator of poor outcome in esophageal cancer. Oncology Letters, 2019, 17, 3826-3834.	1.8	19
103	Expression of CCCTCâ€binding factor (CTCF) is linked to poor prognosis in prostate cancer. Molecular Oncology, 2020, 14, 129-138.	4.6	19
104	MMR deficiency in urothelial carcinoma of the bladder presents with temporal and spatial homogeneity throughout the tumor mass. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 488-495.	1.6	19
105	Diagnostic and prognostic impact of cytokeratin 19 expression analysis in human tumors: a tissue microarray study of 13,172 tumors. Human Pathology, 2021, 115, 19-36.	2.0	19
106	Prevalence and clinical significance of VHL mutations and 3p25 deletions in renal tumor subtypes. Oncotarget, 2020, 11, 237-249.	1.8	19
107	Diverse expression patterns of the <scp>EMT</scp> suppressor grainyheadâ€like 2 (<scp>GRHL</scp>2) in normal and tumour tissues. International Journal of Cancer, 2016, 138, 949-963.	5.1	18
108	Aquaporin 5 expression is frequent in prostate cancer and shows a dichotomous correlation with tumor phenotype and PSA recurrence. Human Pathology, 2016, 48, 102-110.	2.0	18

#	Article	IF	Citations
109	Identification of a High-Level MET Amplification in CTCs and cfTNA of an ALK-Positive NSCLC Patient Developing Evasive Resistance to Crizotinib. Journal of Thoracic Oncology, 2018, 13, e243-e246.	1.1	18
110	Subcellular Compartmentalization of Survivin is Associated with Biological Aggressiveness and Prognosis in Prostate Cancer. Scientific Reports, 2020, 10, 3250.	3.3	18
111	Carboxypeptidase A1 (CPA1) Immunohistochemistry Is Highly Sensitive and Specific for Acinar Cell Carcinoma (ACC) of the Pancreas. American Journal of Surgical Pathology, 2022, 46, 97-104.	3.7	18
112	Upregulation of centromere protein F is linked to aggressive prostate cancers. Cancer Management and Research, 2018, Volume 10, 5491-5504.	1.9	17
113	Aberrant expression of membranous carbonic anhydrase IX (CAIX) is associated with unfavorable disease course in papillary and clear cell renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 531.e19-531.e25.	1.6	17
114	High homogeneity of mismatch repair deficiency in advanced prostate cancer. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2020, 476, 745-752.	2.8	17
115	High-grade intratumoral tumor budding is a predictor for lymphovascular invasion and adverse outcome in stage II colorectal cancer. International Journal of Colorectal Disease, 2020, 35, 259-268.	2.2	17
116	TIP5 primes prostate luminal cells for the oncogenic transformation mediated by PTEN -loss. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 3637-3647.	7.1	17
117	High-Level HOOK3 Expression Is an Independent Predictor of Poor Prognosis Associated with Genomic Instability in Prostate Cancer. PLoS ONE, 2015, 10, e0134614.	2.5	16
118	Overexpression of the A Disintegrin and Metalloproteinase ADAM15 is linked to a Small but Highly Aggressive Subset of Prostate Cancers. Neoplasia, 2017, 19, 279-287.	5.3	16
119	Highâ€Level Glyoxalase 1 (GLO1) expression is linked to poor prognosis in prostate cancer. Prostate, 2017, 77, 1528-1538.	2.3	16
120	<scp>EZH</scp>2 overexpression in head and neck cancer is related to lymph node metastasis. Journal of Oral Pathology and Medicine, 2018, 47, 240-245.	2.7	16
121	High BCAR1 expression is associated with early PSA recurrence in ERG negative prostate cancer. BMC Cancer, 2018, 18, 37.	2.6	16
122	High B7â€H3 expression is linked to increased risk of prostate cancer progression. Pathology International, 2020, 70, 733-742.	1.3	16
123	FGFR1 Amplification Is Often Homogeneous and Strongly Linked to the Squamous Cell Carcinoma Subtype in Esophageal Carcinoma. PLoS ONE, 2015, 10, e0141867.	2.5	16
124	FOXA1 expression is a strong independent predictor of early PSA recurrence in ERG negative prostate cancers treated by radical prostatectomy. Carcinogenesis, 2017, 38, 1180-1187.	2.8	15
125	Quantification of telomere features in tumor tissue sections by an automated 3D imaging-based workflow. Methods, 2017, 114, 60-73.	3.8	15
126	CAIX furthers tumour progression in the hypoxic tumour microenvironment of esophageal carcinoma and is a possible therapeutic target. Journal of Enzyme Inhibition and Medicinal Chemistry, 2018, 33, 1024-1033.	5.2	15

#	Article	IF	Citations
127	Homogeneous MMR Deficiency Throughout the Entire Tumor Mass Occurs in a Subset of Colorectal Neuroendocrine Carcinomas. Endocrine Pathology, 2020, 31, 182-189.	9.0	15
128	Cytokeratin 7 and cytokeratin 20 expression in cancer: A tissue microarray study on 15,424 cancers. Experimental and Molecular Pathology, 2022, 126, 104762.	2.1	15
129	Trophoblast Cell Surface Antigen 2 Expression in Human Tumors: A Tissue Microarray Study on 18,563 Tumors. Pathobiology, 2022, 89, 245-258.	3.8	15
130	Î²III-tubulin overexpression is linked to aggressive tumor features and shortened survival in clear cell renal cell carcinoma. World Journal of Urology, 2015, 33, 1561-1569.	2.2	14
131	The zinc-finger transcription factor SALL4 is frequently expressed in human cancers: association with clinical outcome in squamous cell carcinoma but not in adenocarcinoma of the esophagus. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2016, 468, 483-492.	2.8	14
132	Highâ€level Î²<scp>III</scp>â€tubulin overexpression occurs in most head and neck cancers but is unrelated to clinical outcome. Journal of Oral Pathology and Medicine, 2017, 46, 986-990.	2.7	14
133	The impact of variant histological differentiation on extranodal extension and survival in node positive bladder cancer treated with radical cystectomy. Surgical Oncology, 2019, 28, 208-213.	1.6	14
134	Loss of p16 and high Ki67 labeling index is associated with poor outcome in esophageal carcinoma. Oncotarget, 2020, 11, 1007-1016.	1.8	14
135	Prognostic value of alpha-methyl CoA racemase (AMACR) expression in renal cell carcinoma. World Journal of Urology, 2013, 31, 847-853.	2.2	13
136	Prevalence of chromosomal rearrangements involving non-ETS genes in prostate cancer. International Journal of Oncology, 2015, 46, 1637-1642.	3.3	13
137	Reduced anoctamin 7 (ANO7) expression is a strong and independent predictor of poor prognosis in prostate cancer. Cancer Biology and Medicine, 2021, 18, 245-255.	3.0	13
138	Y-chromosome loss is frequent in male renal tumors. Annals of Translational Medicine, 2021, 9, 209-209.	1.7	13
139	Expression of DNA ligase IV is linked to poor prognosis and characterizes a subset of prostate cancers harboring TMPRSS2:ERG fusion and PTEN deletion. Oncology Reports, 2015, 34, 1211-1220.	2.6	12
140	Immune Exclusion Is Frequent in Small-Cell Carcinoma of the Bladder. Disease Markers, 2019, 2019, 1-6.	1.3	12
141	Biperiden and mepazine effectively inhibit MALT1 activity and tumor growth in pancreatic cancer. International Journal of Cancer, 2020, 146, 1618-1630.	5.1	12
142	Epithelial splicing regulatory protein 1 and 2 (ESRP1 and ESRP2) upregulation predicts poor prognosis in prostate cancer. BMC Cancer, 2020, 20, 1220.	2.6	12
143	Napsin A Expression in Human Tumors and Normal Tissues. Pathology and Oncology Research, 2021, 27, 613099.	1.9	12
144	Pattern of placental alkaline phosphatase (<scp>PLAP</scp>) expression in human tumors: a tissue microarray study on 12,381 tumors. Journal of Pathology: Clinical Research, 2021, 7, 577-589.	3.0	12

#	Article	IF	Citations
145	Impact of the Ki-67 labeling index and p53 expression status on disease-free survival in pT1 urothelial carcinoma of the bladder. Translational Andrology and Urology, 2017, 6, 1018-1026.	1.4	12
146	Reply to A. Italiano. Journal of Clinical Oncology, 2011, 29, 4718-4719.	1.6	11
147	Activated leukocyte cell adhesion molecule (ALCAM/CD166) expression in head and neck squamous cell carcinoma (HNSSC). Pathology Research and Practice, 2014, 210, 649-655.	2.3	11
148	Prevalence of fibroblast growth factor receptor 1 (FGFR1) amplification in squamous cell carcinomas of the head and neck. Journal of Cancer Research and Clinical Oncology, 2018, 144, 53-61.	2.5	11
149	High level of EZH2 expression is linked to high density of CD8-positive T-lymphocytes and an aggressive phenotype in renal cell carcinoma. World Journal of Urology, 2021, 39, 481-490.	2.2	11
150	Tumor cell PD-L1 expression is a strong predictor of unfavorable prognosis in immune checkpoint therapy-naive clear cell renal cell cancer. International Urology and Nephrology, 2021, 53, 2493-2503.	1.4	11
151	Cytokeratin 5 and cytokeratin 6 expressions are unconnected in normal and cancerous tissues and have separate diagnostic implications. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2022, 480, 433-447.	2.8	11
152	Immunohistochemically detectable thyroglobulin expression in extrathyroidal cancer is 100% specific for thyroidal tumor origin. Annals of Diagnostic Pathology, 2021, 54, 151793.	1.3	11
153	DOG1 expression is common in human tumors: A tissue microarray study on more than 15,000 tissue samples. Pathology Research and Practice, 2021, 228, 153663.	2.3	11
154	Tissue microarrays for early target evaluation. Drug Discovery Today: Technologies, 2004, 1, 41-48.	4.0	10
155	Saccharomyces cerevisiaeâ€“like 1 overexpression is frequent in prostate cancer and has markedly different effects in Ets-related gene fusionâ€“positive and fusion-negative cancers. Human Pathology, 2015, 46, 514-523.	2.0	10
156	Comparison of 11 Active Surveillance Protocols in Contemporary European Men Treated With Radical Prostatectomy. Clinical Genitourinary Cancer, 2018, 16, e141-e149.	1.9	10
157	High expression of class III Î²â€‘tubulin in upper gastrointestinal cancer types. Oncology Letters, 2018, 16, 7139-7145.	1.8	10
158	Claudin-1 upregulation is associated with favorable tumor features and a reduced risk for biochemical recurrence in ERG-positive prostate cancer. World Journal of Urology, 2020, 38, 2185-2196.	2.2	10
159	Reduced KLK2 expression is a strong and independent predictor of poor prognosis in ERGâ€negative prostate cancer. Prostate, 2020, 80, 1097-1107.	2.3	10
160	MUC5AC Expression in Various Tumor Types and Nonneoplastic Tissue: A Tissue Microarray Study on 10â€…399 Tissue Samples. Technology in Cancer Research and Treatment, 2021, 20, 153303382110433.	1.9	10
161	High density of cytotoxic T-lymphocytes is linked to tumoral PD-L1 expression regardless of the mismatch repair status in colorectal cancer. Acta OncolÃ³gica, 2021, 60, 1210-1217.	1.8	10
162	Family with sequence similarity 13C (FAM13C) overexpression is an independent prognostic marker in prostate cancer. Oncotarget, 2017, 8, 31494-31508.	1.8	10

#	Article	IF	Citations
163	Increased ERCC1 expression is linked to chromosomal aberrations and adverse tumor biology in prostate cancer. BMC Cancer, 2017, 17, 504.	2.6	9
164	Reduced RBM3 expression is associated with aggressive tumor features in esophageal cancer but not significantly linked to patient outcome. BMC Cancer, 2018, 18, 1106.	2.6	9
165	The independent prognostic impact of the GATA2 pioneering factor is restricted to ERG-negative prostate cancer. Tumor Biology, 2019, 41, 101042831882481.	1.8	9
166	A pre-specified model based on four kallikrein markers in blood improves predictions of adverse pathology and biochemical recurrence after radical prostatectomy. British Journal of Cancer, 2020, 123, 604-609.	6.4	9
167	Elevated MUC5AC expression is associated with mismatch repair deficiency and proximal tumor location but not with cancer progression in colon cancer. Medical Molecular Morphology, 2021, 54, 156-165.	1.0	9
168	Upregulation of SPDEF is associated with poor prognosis in prostate cancer. Oncology Letters, 2019, 18, 5107-5118.	1.8	9
169	Expression of Epithelialâ˜'Mesenchymal Transition Regulating Transcription Factors in Head and Neck Squamous Cell Carcinomas. , 2017, 37, 5435-5440.		9
170	Determination of Tumor Heterogeneity in Colorectal Cancers Using Heterogeneity Tissue Microarrays. Pathology and Oncology Research, 2015, 21, 1183-1189.	1.9	8
171	Survivin expression in head and neck squamous cell carcinomas is frequent and correlates with clinical parameters and treatment outcomes. Clinical Oral Investigations, 2019, 23, 361-367.	3.0	8
172	8p deletions in renal cell carcinoma are associated with unfavorable tumor features and poor overall survival. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 43.e13-43.e20.	1.6	8
173	Upregulation of PTTG1 is associated with poor prognosis in prostate cancer. Pathology International, 2020, 70, 441-451.	1.3	8
174	Heterogeneity and chronology of 6q15 deletion and ERG-fusion in prostate cancer. Oncotarget, 2016, 7, 3897-3904.	1.8	8
175	Expression of the immune checkpoint receptor TIGIT in seminoma. Oncology Letters, 2019, 18, 1497-1502.	1.8	7
176	Selectin Binding Sites Are Involved in Cell Adhesive Properties of Head and Neck Squamous Cell Carcinoma. Cancers, 2019, 11, 1672.	3.7	7
177	SNW1 is a prognostic biomarker in prostate cancer. Diagnostic Pathology, 2019, 14, 33.	2.0	7
178	Secreted Frizzled-Related Protein 4 (SFRP4) Is an Independent Prognostic Marker in Prostate Cancers Lacking TMPRSS2: ERG Fusions. Pathology and Oncology Research, 2020, 26, 2709-2722.	1.9	7
179	Increased Cytoplasmic CD138 Expression Is Associated with Aggressive Characteristics in Prostate Cancer and Is an Independent Predictor for Biochemical Recurrence. BioMed Research International, 2020, 2020, 1-13.	1.9	7
180	Prognostic markers in pT3 bladder cancer: A study from the international bladder cancer tissue microarray project. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 301.e17-301.e28.	1.6	7

#	Article	IF	Citations
181	PITX1 Is a Regulator of TERT Expression in Prostate Cancer with Prognostic Power. Cancers, 2022, 14, 1267.	3.7	7
182	Angiotensin-Converting Enzyme 2 Protein Is Overexpressed in a Wide Range of Human Tumour Types: A Systematic Tissue Microarray Study on >15,000 Tumours. Biomedicines, 2021, 9, 1831.	3.2	7
183	Up regulation of the steroid hormone synthesis regulator HSD3B2 is linked to early PSA recurrence in prostate cancer. Experimental and Molecular Pathology, 2018, 105, 50-56.	2.1	6
184	Hyperparameter optimization for image analysis: application to prostate tissue images and live cell data of virus-infected cells. International Journal of Computer Assisted Radiology and Surgery, 2019, 14, 1847-1857.	2.8	6
185	Upregulation of the heterogeneous nuclear ribonucleoprotein hnRNPA1 is an independent predictor of early biochemical recurrence in TMPRSS2:ERG fusion-negative prostate cancers. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2020, 477, 625-636.	2.8	6
186	Reduced membranous MET expression is linked to bladder cancer progression. Cancer Genetics, 2014, 207, 147-152.	0.4	5
187	The Aging Prostate Is Never â€œNormalâ€• Implications from the Genomic Characterization of Multifocal Prostate Cancers. European Urology, 2015, 68, 348-350.	1.9	5
188	Down-Regulation of S100A8 is an Independent Predictor of PSA Recurrence in Prostate Cancer Treated by Radical Prostatectomy. Neoplasia, 2019, 21, 872-881.	5.3	5
189	Loss of cytoplasmic survivin expression is an independent predictor of poor prognosis in radically operated prostate cancer patients. Cancer Medicine, 2020, 9, 1409-1418.	2.8	5
190	Upregulation of the transcription factor TFAP2D is associated with aggressive tumor phenotype in prostate cancer lacking the TMPRSS2:ERG fusion. Molecular Medicine, 2020, 26, 24.	4.4	5
191	High CHK2 protein expression is a strong and independent prognostic feature in ERG negative prostate cancer. Pathology, 2020, 52, 421-430.	0.6	5
192	Opposing prognostic relevance of junction plakoglobin in distinct prostate cancer patient subsets. Molecular Oncology, 2021, 15, 1956-1969.	4.6	5
193	Nuclear ELAC2 overexpression is associated with increased hazard for relapse after radical prostatectomy. Oncotarget, 2019, 10, 4973-4986.	1.8	5
194	Semi-automated validation and quantification of CTLA-4 in 90 different tumor entities using multiple antibodies and artificial intelligence. Laboratory Investigation, 2022, 102, 650-657.	3.7	5
195	VEGFR-1 Overexpression Identifies a Small Subgroup of Aggressive Prostate Cancers in Patients Treated by Prostatectomy. International Journal of Molecular Sciences, 2015, 16, 8591-8606.	4.1	4
196	Evaluating Guideline Adherence for T1 Bladder Cancer Treatment and Surveillance: A Retrospective German Multicenter Observation. Urologia Internationalis, 2018, 101, 285-292.	1.3	4
197	High-level expression of protein tyrosine phosphatase non-receptor 12 is a strong and independent predictor of poor prognosis in prostate cancer. BMC Cancer, 2019, 19, 944.	2.6	4
198	Loss of CCAATâ€enhancerâ€binding protein alpha (CEBPA) is linked to poor prognosis in PTEN deleted and TMPRSS2:ERG fusion type prostate cancers. Prostate, 2019, 79, 302-311.	2.3	4

#	Article	IF	Citations
199	5q21 deletion is often heterogeneous in prostate cancer. Genes Chromosomes and Cancer, 2019, 58, 509-515.	2.8	4
200	Differential regulation of extracellular matrix proteins in three recurrent liver metastases of a single patient with colorectal cancer. Clinical and Experimental Metastasis, 2020, 37, 649-656.	3.3	4
201	Upregulation of Phosphatase 1 Nuclear-Targeting Subunit (PNUTS) Is an Independent Predictor of Poor Prognosis in Prostate Cancer. Disease Markers, 2020, 2020, 1-10.	1.3	4
202	Loss of the adhesion molecule CEACAM1 is associated with early biochemical recurrence in TMPRSS2:ERG fusionâ€positive prostate cancers. International Journal of Cancer, 2020, 147, 575-583.	5.1	4
203	Prostate cancer grading, time to go back to the future. BJU International, 2021, 127, 165-168.	2.5	4
204	DOG1 is commonly expressed in pancreatic adenocarcinoma but unrelated to cancer aggressiveness. PeerJ, 2021, 9, e11905.	2.0	4
205	Nuclear up regulation of the BRCA1-associated ubiquitinase BAP1 is associated with tumor aggressiveness in prostate cancers lacking the TMPRSS2:ERG fusion. Oncotarget, 2019, 10, 7096-7111.	1.8	4
206	Large-scale human tissue analysis identifies Uroplakin 1b as a putative diagnostic marker in surgical pathology. Human Pathology, 2022, 126, 108-120.	2.0	4
207	Reply to V. Arena et al. Journal of Clinical Oncology, 2009, 27, e9-e10.	1.6	3
208	Deletion of 3p13 is a late event linked to progression of TMPRSS2:ERG fusion prostate cancer. Cancer Management and Research, 2018, Volume 10, 5909-5917.	1.9	3
209	Chromosome 17p13 deletion is associated with an aggressive tumor phenotype in clear cell renal cell carcinoma. World Journal of Surgical Oncology, 2020, 18, 128.	1.9	3
210	Chromosomal deletion of 9p21 is linked to poor patient prognosis in papillary and clear cell kidney cancer. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 605.e1-605.e8.	1.6	3
211	A non-diploid DNA status is linked to poor prognosis in renal cell cancer. World Journal of Urology, 2021, 39, 829-837.	2.2	3
212	Mismatch repair deficiency occurs very rarely in seminomas. Translational Andrology and Urology, 2021, 10, 1048-1055.	1.4	3
213	High mitochondrial content is associated with breast cancer aggressiveness. Molecular and Clinical Oncology, 2021, 15, 203.	1.0	3
214	CHD1 loss negatively influences metastasis-free survival in R0-resected prostate cancer patients and promotes spontaneous metastasis in vivo. Cancer Gene Therapy, 2022, 29, 49-61.	4.6	3
215	Estrogen receptor alpha (<i>ESR1</i>) gene amplification status and clinical outcome in tamoxifen-treated postmenopausal patients with endocrine-responsive early breast cancer: An analysis of the prospective ABCSG-6 trial.. Journal of Clinical Oncology, 2012, 30, 10501-10501.	1.6	3
216	Cytological Diagnostic Procedures in Malignant Mesothelioma. Advances in Experimental Medicine and Biology, 2021, , 41-49.	1.6	3

#	Article	IF	Citations
217	Qualitative and Quantitative Requirements for Assessing Prognostic Markers in Prostate Cancer. Microarrays (Basel, Switzerland), 2014, 3, 137-158.	1.4	2
218	CD151 expression is frequent but unrelated to clinical outcome in head and neck cancer. Clinical Oral Investigations, 2017, 21, 1503-1508.	3.0	2
219	Loss of PSP94 expression is associated with early PSA recurrence and deteriorates outcome of PTEN deleted prostate cancers. Cancer Biology and Medicine, 2019, 16, 319.	3.0	2
220	Ectopic Expression of Hematopoietic SHIP1 in Human Colorectal Cancer. Biomedicines, 2020, 8, 215.	3.2	2
221	Recommendations for immunocytochemistry in lung cancer typing: An update on a resourceâ€efficient approach with largeâ€scale comparative Bayesian analysis. Cytopathology, 2021, , .	0.7	2
222	Prognostic utility of the recently recommended histologic classification and revised TNM staging system of renal cell carcinoma. Cancer, 2000, 89, 604-614.	4.1	2
223	Value of cell cycle progression (CCP) score to predict biochemical recurrence and definitive post-surgical pathology.. Journal of Clinical Oncology, 2013, 31, 5043-5043.	1.6	2
224	Concomitant mutation and amplification of the ERBB2 (HER2) gene in human tumors.. Journal of Clinical Oncology, 2014, 32, 11071-11071.	1.6	2
225	A nuclear shift of GSK3Î² protein is an independent prognostic factor in prostate cancer. Oncotarget, 2019, 10, 1729-1744.	1.8	2
226	Large-Scale Tissue Microarray Evaluation Corroborates High Specificity of High-Level Arginase-1 Immunostaining for Hepatocellular Carcinoma. Diagnostics, 2021, 11, 2351.	2.6	2
227	VPRBP Functions Downstream of the Androgen Receptor and OGT to Restrict p53 Activation in Prostate Cancer. Molecular Cancer Research, 2022, 20, 1047-1060.	3.4	2
228	Current Therapies of Wilms Tumors in the Adult: Diagnostic Considerations and Treatment Challenges. Clinical Genitourinary Cancer, 2019, 17, e522-e525.	1.9	1
229	Increased lysophosphatidylcholine acyltransferase 1 expression is unrelated to prognosis of esophageal cancer patients. Journal of Cancer Research and Clinical Oncology, 2021, 147, 2879-2884.	2.5	1
230	E-selectin ligand binding affinity to determine anti-metastatic efficacy of proteasome inhibition.. Journal of Clinical Oncology, 2016, 34, e23010-e23010.	1.6	1
231	6q deletion is frequent but unrelated to patient prognosis in breast cancer. Breast Cancer, 2021, , 1.	2.9	1
232	HER2 gene amplification testing by fluorescence in situ hybridization (FISH): Comparison of the ASCO-CAP guidelines with FISH scores used for enrollment in breast cancer international research group (BCIRG) clinical trials.. Journal of Clinical Oncology, 2016, 34, 515-515.	1.6	1
233	Effect of mast cells on efficacy of anti-angiogenic therapy by secreting matrix-degrading granzyme b.. Journal of Clinical Oncology, 2017, 35, 11522-11522.	1.6	1
234	Combination of Biochemical and Cytological Findings for Better Diagnosis in Pleural Effusions. Advances in Experimental Medicine and Biology, 2022, , 51.	1.6	1

#	Article	IF	Citations
235	Mucin 5AC expression is common but unrelated to tumor progression in pancreatic adenocarcinoma. International Journal of Immunopathology and Pharmacology, 2022, 36, 039463202211065.	2.1	1
236	Tissue microarrays. , 2005, , .		0
237	Reply to R. Simon. Journal of Clinical Oncology, 2011, 29, 2941-2944.	1.6	0
238	Î²III-tubulin overexpression is linked to left-sided tumor localization and nuclear Î²-catenin expression in colorectal cancer. Cancer Treatment Communications, 2015, 4, 96-102.	0.4	0
239	Abstract 2735: Clinical significance of CD4+CD7â^'helper T-cells and tumoral CD7 expression in colorectal cancer. , 2021, , .		0
240	Abstract 2833: Mesothelin expression in human tumor types: a tissue microarray study on more than 13,000 tumor samples. , 2021, , .		0
241	Abstract 2773: Deep profiling of the PD-1/PD-L1 pathway in 10000 cancers revealed changes in the immune cell composition between cancer entities. , 2021, , .		0
242	Abstract 2775: PD-L1 expression in human tumors: a tissue microarray study on 5,561 tissue samples and 87 tumor types. , 2021, , .		0
243	Abstract 2750: Prognostic impact of tumor infiltrating lymphocytes in the tumor microenvironment of vulvar squamous cell carcinoma. , 2021, , .		0
244	Prognostic Molecular Features in Diffuse Large B-Cell Lymphoma from Saudi Arabia.. Blood, 2004, 104, 4609-4609.	1.4	0
245	Epstein-Barr Virus Infection Is Not the Sole Cause of High Prevalence for Hodgkinâ€™s Lymphoma in Saudi Arabia.. Blood, 2004, 104, 3120-3120.	1.4	0
246	Association of nuclear accumulation of p53 with ERG fusion and poor prognosis in prostate cancer.. Journal of Clinical Oncology, 2012, 30, 124-124.	1.6	0
247	The combination of DNA ploidy status and PTEN/6q15 deletions to provide strong and independent prognostic information in prostate cancer.. Journal of Clinical Oncology, 2015, 33, 5027-5027.	1.6	0
248	Long-term follow-up of bone marrow micrometastases in colon cancer patients.. Journal of Clinical Oncology, 2015, 33, 3529-3529.	1.6	0
249	A pre-specified statistical model based on four kallikrein markers in blood to predict advanced pathology on radical prostatectomy.. Journal of Clinical Oncology, 2018, 36, 5073-5073.	1.6	0
250	Web-based Prostate Visualization Tool. Current Directions in Biomedical Engineering, 2020, 6, 563-566.	0.4	0
251	Abstract P068: Automated cell type specific PD-L1 quantification by artificial intelligence using high throughput bleach & stain 15-marker multiplex fluorescence immunohistochemistry in human cancers. , 2022, , .		0
252	Abstract P069: Semi-automated validation and quantification of CTLA-4 in 90 different Tumor entities using multiple antibodies and artificial intelligence. , 2022, , .		0

#	Article	IF	Citations
253	Immune phenotypes and T-cell density at the invasive margin correlate with prognosis in epithelial vulvar cancer.. Journal of Clinical Oncology, 2022, 40, 5599-5599.	1.6	0